104708-12-5

Upstream product

• 1132108-81-6 (4R)-5,5-dimethyl-4-hydroxymethyl-2-phenyl-1,3-dioxane 
• 98-59-9 p-toluenesulfonyl chloride 
• 774-48-1 (diethoxymethyl)benzene 
• 599-04-2 (R)-Pantolacton 
• 60856-63-5 (2R)-(-)-3,3-dimethylbutane-1,2,4-triol 

Downstream Products

• 1572039-76-9 (4R)-4-azidomethyl-5,5-dimethyl-2-phenyl-1,3-dioxane 
• 1572039-77-0 (4R)-4-aminomethyl-5,5-dimethyl-2-phenyl-1,3-dioxane 
• 1572039-78-1 4-nitrophenyl-[((4R)-5,5-dimethyl-2-phenyl-1,3-dioxan-4-yl)methyl]sulfamate 
• 104708-14-7 (3R)-2,2-dimethyl-3,4-epoxybutyl benzoate 
• 104745-13-3 Benzoic acid (R)-4,4-dimethyl-tetrahydro-furan-3-yl ester 
• 104708-05-6 Benzoic acid (R)-3-hydroxy-2,2-dimethyl-4-(toluene-4-sulfonyloxy)-butyl ester 
• 104708-13-6 Benzoic acid (R)-3-hydroxy-2,2-dimethyl-1-(toluene-4-sulfonyloxymethyl)-propyl ester 

Relevant academic research and scientific papers

Reaction intermediate analogues as bisubstrate inhibitors of pantothenate synthetase

The biosynthesis of pantothenate, the core of coenzyme A (CoA), has been considered an attractive target for the development of antimicrobial agents since this pathway is essential in prokaryotes, but absent in mammals. Pantothenate synthetase, encoded by the gene panC, catalyzes the final condensation of pantoic acid with β-alanine to afford pantothenate via an intermediate pantoyl adenylate. We describe the synthesis and biochemical characterization of five PanC inhibitors that mimic the intermediate pantoyl adenylate. These inhibitors are competitive inhibitors with respect to pantoic acid and possess submicromolar to micromolar inhibition constants. The observed SAR is rationalized through molecular docking studies based on the reported co-crystal structure of 1a with PanC. Finally, whole cell activity is assessed against wild-type Mtb as well as a PanC knockdown strain where PanC is depleted to less than 5% of wild-type levels.